Clinical Trials

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07221253 2026-03-17

AB02

1,100 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT06667908 2026-03-16

CONVERGE

130 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06780137 2026-03-16

MK-6070-002

Phase 1/2 Recruiting

262 enrolled

Small Cell Lung Carcinoma

NCT05061550 2026-03-11

NeoCOAST-2

630 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04900818 2026-03-05

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

330 enrolled

Adenocarcinoma Of Esophagus, Biliary Tract Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT06890598 2026-03-03

SUNRAY-02

700 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06992609 2026-03-02

ALBORAN

70 enrolled

Small Cell Lung Carcinoma

NCT07005128 2026-02-27

DeLLphi-312

330 enrolled

Small Cell Lung Carcinoma

NCT06282575 2026-02-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

286 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04379596 2026-02-23

DG-03

450 enrolled

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05211895 2026-02-23

PACIFIC-8

860 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06960577 2026-02-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06467357 2026-02-17

DESTINY-BTC01

620 enrolled

Biliary Tract Neoplasms

NCT06898957 2026-02-05

(DeLLphi-310)

200 enrolled

Small Cell Lung Carcinoma

NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

604 enrolled

Advanced Biliary Tract Cancer

NCT07174583 2026-01-23

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Phase 1/2 Recruiting

208 enrolled

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

50 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT07081633 2025-12-30

TREMENDOUS-2

114 enrolled

Carcinoma, Hepatocellular

NCT06252753 2025-12-26

LIVER-R

Recruiting

4,490 enrolled

Hepatobiliary Cancers

NCT05733598 2025-12-15

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

60 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT04686305 2025-11-13

DL03

244 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06117891 2025-11-12

REFINE-IO

Recruiting

300 enrolled

Unresectable Hepatocellular Carcinoma

NCT06008093 2025-10-27

TRITON

280 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04644289 2025-10-03

WoO

60 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

NCT06463665 2025-09-26

VIRO-25

142 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT06109272 2025-08-15

LIVIGNO-2

Phase 2/3 Recruiting

660 enrolled

Carcinoma, Hepatocellular

NCT05742607 2025-05-16

MATISSE

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05557838 2025-02-07

TREMENDOUS

210 enrolled

Carcinoma, Hepatocellular

NCT06611345 2024-10-26

A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers

Phase NA Recruiting

60 enrolled